Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT01022138 Terminated - Breast Cancer Clinical Trials

Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer

Start date: March 8, 2010
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Treating a patient's T cells in the laboratory may help the T cells kill more tumor cells when they are put back in the body. Giving laboratory-treated T cells after chemotherapy may be an effective treatment for breast cancer. PURPOSE: This phase II trial is studying how well giving laboratory-treated T cells after second-line chemotherapy works in treating patients with HER2/neu-negative metastatic breast cancer.

NCT ID: NCT01022086 Recruiting - Clinical trials for Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)

Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab

Start date: November 2009
Phase: N/A
Study type: Observational

Herceptin has shown significant improvement in breast cancer therapy and improved survival of patients over-expressing the HER-2 protein by 50%. However, Herceptin has shown to negatively affect the heart, and frequent heart monitoring with multiple gated acquisition (MUGA) scans is required. MUGA scans use radiation and are not very accurate. This study will use cardiac magnetic resonance images (CMRs) to evaluate heart function and compare to MUGA scans in patients receiving Herceptin for early-stage breast cancer. In addition, novel biomarkers will also be assessed at the same time to help identify possible patients at risk for developing heart toxicities.

NCT ID: NCT01019616 Active, not recruiting - Clinical trials for Primary Breast Cancer

Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy

Start date: March 4, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this phase Ⅲ, multi-center, prospective, open-label, randomized,controlled study is to determine whether alternative non-cross-resistant adjuvant chemotherapy can increase distant disease free survival(DDFS) in operable patients non-response to primary chemotherapy.

NCT ID: NCT01019577 Completed - Clinical trials for Metastatic Breast Cancer

Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant

Start date: October 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the response rates for Ixabepilone (BMS-247550) in subjects with metastatic breast cancer previously treated with an anthracycline and who are taxane resistant.

NCT ID: NCT01019512 Terminated - Breast Cancer Clinical Trials

Flexitouch Lymphedema System in Treating Stage II Lymphedema in Patients With Breast Cancer

Start date: July 2009
Phase: N/A
Study type: Interventional

RATIONALE: The Flexitouch lymphedema system may lessen lymphedema caused by treatment for breast cancer. It is not yet known whether the Flexitouch lymphedema system is more effective than complex decongestive therapy in treating lymphedema. PURPOSE: This randomized clinical trial is studying the Flexitouch lymphedema system in treating stage II lymphedema in patients with breast cancer.

NCT ID: NCT01018251 Withdrawn - Clinical trials for Adult Women With a New Diagnosis of Invasive Breast Cancer (Have Not Undergone Treatment)

Positron Emission Tomography in Monitoring Treatment Response in Women With Newly Diagnosed Breast Cancer

Start date: March 2009
Phase: N/A
Study type: Interventional

This study will investigate the sensitivity and specificity of FLT-PET/CT in primary breast cancer detection and in the use of FLT-PET in monitoring how well a breast tumor respond to treatment. We will compare this technique with other imaging modalities as well as with tissue collection (during a biopsy). We will recruit women with a newly diagnosed invasive breast cancer, who are able to tolerate undergoing a PET/CT (possibly two scans) scan,

NCT ID: NCT01018108 Completed - Breast Cancer Clinical Trials

Visualization of the Effect of Acupuncture on Brain Serotonin in Breast Cancer Survivors

Start date: March 2009
Phase: Phase 1
Study type: Interventional

RATIONALE: New imaging procedures, such as single photon emission computed tomography, may help in learning how acupuncture affects serotonin levels in the brain of breast cancer survivors. PURPOSE: This phase I trial is studying the best way to visualize the effect of acupuncture on brain serotonin in breast cancer survivors.

NCT ID: NCT01017549 Completed - Breast Cancer Clinical Trials

Post Market Study Using the Xoft Axxent System

Start date: March 26, 2007
Phase: N/A
Study type: Interventional

The purpose of this multi-center clinical study is to compile post market performance and safety data on the Axxent System.

NCT ID: NCT01017185 Completed - Malignant Melanoma Clinical Trials

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Start date: August 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether HF10 is safe and effective in the treatment of head and neck cancer or solid tumors with cutaneous and/or superficial lesions.

NCT ID: NCT01015963 Completed - Breast Cancer Clinical Trials

Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871

Start date: October 2008
Phase: N/A
Study type: Observational

This research trial studies deoxyribonucleic acid (DNA) in blood samples from Caucasian and African-American cancer patients who received docetaxel on clinical trial CLB-9871. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about how docetaxel is used by the body.